Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: A randomized substudy of the ViTATOPS trial

Epidemiological and laboratory studies suggest that increasing concentrations of plasma homocysteine (total homocysteine [tHcy]) accelerate cardiovascular disease by promoting vascular inflammation, endothelial dysfunction, and hypercoagulability. We conducted a randomized controlled trial in 285 pa...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2005, Vol.36 (1), p.144-146
Hauptverfasser:	DUSITANOND, P, EIKELBOOM, J. W, BAKER, R, JAMROZIK, K, HANKEY, G. J, THOM, J, GILMORE, G, LOH, K, YI, Q, KLIJN, C. J. M, LANGTON, P, VAN BOCKXMEER, F. M
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Biomarkers - blood Blood Coagulation Cardiovascular Diseases - etiology Cardiovascular system Endothelium, Vascular - metabolism Folic Acid - therapeutic use Homocysteine - blood Humans Inflammation - blood Ischemic Attack, Transient - blood Ischemic Attack, Transient - drug therapy Medical sciences Neurology Neuropharmacology Neuroprotective agent Pharmacology. Drug treatments Pyridoxine - therapeutic use Risk Factors Stroke - blood Stroke - drug therapy Vascular diseases and vascular malformations of the nervous system Vasodilator agents. Cerebral vasodilators Vitamin B 12 - therapeutic use Vitamin B Complex - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!